Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients

NCT00044538 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: BAY59-8862 (Cytotoxic Taxane)

Sponsor

Bayer